Integrium works with specialty, development-stage, mid-size, and large biopharmaceutical and medical device companies, providing a complete range of clinical trial management services for Phase I through Phase IV dermatology, cardiovascular and metabolic disease studies.
Integrium team has implemented Phase Forward IRT because of its technology, rapid deployment and streamlined workflow to support advanced clinical trial planning and management.
Phase Forward’s CRO partnership strategy is designed to assist CRO clients in achieving success in both the short and long term. Its customized structure and flexible pricing options help CROs of all sizes to invest in their own capabilities and capitalize on new growth opportunities.
Eileen McAuley, chief operating officer of Integrium, said: “We implemented Phase Forward IRT because we were impressed by the capabilities of the technology, Phase Forward’s reputation and the potential to adopt additional products within the company’s suite as our needs evolve over time.”
Scott Dixon, vice president of global CRO partnerships at Phase Forward, said: “We look forward to working with the Integrium team to help deliver the consistent, high-quality results that sponsors count on from the company.”